Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons invivo

Neurobiology of Aging

Volumn 36, Issue 9, 2015, Pages 2617-2627

  Kim, Hyung Wook ^a,b   Choi, Won Seok ^a,c,d   Sorscher, Noah ^a   Park, Hyung Joon ^c,d   Tronche, François ^e,f,g   Palmiter, Richard D ^a,h   Xia, Zhengui ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Sejong University   (South Korea)

^c Chonnam National University   (South Korea)

^d Chonnam National University Medical School   (South Korea)

^e SORBONNE UNIVERSITÉ   (France)

^f Université Pierre et Marie Currie   (France)

^g Médicale Unité Mixte de Recherche en Santé 938   (France)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine neuron; Mitochondrial complex I; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; DOPAMINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; LEVODOPA; NDUFS4 PROTEIN, MOUSE; TUMOR ANTIGEN; TYROSINE 3 MONOOXYGENASE; UBC ANTIGEN;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; ENZYME INHIBITION; FEMALE; GENE; GENE DELETION; IN VIVO STUDY; KNOCKOUT MOUSE; LIFESPAN; MALE; MOTOR DYSFUNCTION; MOUSE; MOUSE MODEL; NDUFS4 GENE; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SUBSTANTIA NIGRA PARS COMPACTA; AGE; ANIMAL; CYTOLOGY; DEFICIENCY; DOSE RESPONSE; DRUG EFFECTS; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MITOCHONDRION; MOTOR ACTIVITY; OXYGEN CONSUMPTION; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; SUBSTANTIA NIGRA; SYNAPTOSOME; ULTRASTRUCTURE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AGE FACTORS; ANIMALS; ANTIGENS, NEOPLASM; DOPAMINE; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON TRANSPORT COMPLEX I; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; LEVODOPA; MALE; MICE; MICE, KNOCKOUT; MITOCHONDRIA; MOTOR ACTIVITY; OXYGEN CONSUMPTION; PSYCHOMOTOR PERFORMANCE; SUBSTANTIA NIGRA; SYNAPTOSOMES; TYROSINE 3-MONOOXYGENASE;

EID: 84940467319     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.05.008     Document Type: Article

References (60)

1. Aarsland D., Taylor J.P., Weintraub D. Psychiatric issues in cognitive impairment. Mov. Disord. 2014, 29:651-662.
2. Abou-Sleiman P.M., Muqit M.M., Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 2006, 7:207-219.
3. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3:1301-1306.
4. Blesa J., Phani S., Jackson-Lewis V., Przedborski S. Classic and new animal models of Parkinson's disease. J.Biomed. Biotechnol. 2012, 2012:845618.
5. Blonder L.X., Slevin J.T. Emotional dysfunction in Parkinson's disease. Behav. Neurol. 2011, 24:201-217.
6. Borutaite V., Brown G.C. Rapid reduction of nitric oxide by mitochondria, and reversible inhibition of mitochondrial respiration by nitric oxide. Biochem. J. 1996, 315(Pt 1):295-299.
7. Budde S.M., van den Heuvel L.P., Janssen A.J., Smeets R.J., Buskens C.A., DeMeirleir L., Van Coster R., Baethmann M., Voit T., Trijbels J.M., Smeitink J.A. Combined enzymatic complex I and III deficiency associated with mutations in the nuclear encoded NDUFS4 gene. Biochem. Biophys. Res. Commun. 2000, 275:63-68.
8. Carvey P.M., Punati A., Newman M.B. Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transpl. 2006, 15:239-250.
9. Choi W.S., Abel G., Klintworth H., Flavell R.A., Xia Z. JNK3 mediates paraquat- and rotenone-induced dopaminergic neuron death. J.Neuropathol. Exp. Neurol. 2010, 69:511-520.
10. Choi W.S., Kruse S.E., Palmiter R.D., Xia Z. Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15136-15141.
11. Choi W.S., Palmiter R.D., Xia Z. Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson's disease model. J.Cell Biol. 2011, 192:873-882.
12. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
13. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302:819-822.
14. Dietz G.P., Stockhausen K.V., Dietz B., Falkenburger B.H., Valbuena P., Opazo F., Lingor P., Meuer K., Weishaupt J.H., Schulz J.B., Bahr M. Membrane-permeable Bcl-xL prevents MPTP-induced dopaminergic neuronal loss in the substantia nigra. J.Neurochem. 2008, 104:757-765.
15. Fraker C., Timmins M.R., Guarino R.D., Haaland P.D., Ichii H., Molano D., Pileggi A., Poggioli R., Presnell S.C., Inverardi L., Zehtab M., Ricordi C. The use of the BD oxygen biosensor system to assess isolated human islets of langerhans: oxygen consumption as a potential measure of islet potency. Cell Transpl. 2006, 15:745-758.
16. Gibrat C., Saint-Pierre M., Bousquet M., Levesque D., Rouillard C., Cicchetti F. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions. J.Neurochem. 2009, 109:1469-1482.
17. Haas R.H., Nasirian F., Nakano K., Ward D., Pay M., Hill R., Shults C.W. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann. Neurol. 1995, 37:714-722.
18. Hirsch E.C., Jenner P., Przedborski S. Pathogenesis of Parkinson's disease. Mov. Disord. 2013, 28:24-30.
19. Inden M., Kitamura Y., Takeuchi H., Yanagida T., Takata K., Kobayashi Y., Taniguchi T., Yoshimoto K., Kaneko M., Okuma Y., Taira T., Ariga H., Shimohama S. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J.Neurochem. 2007, 101:1491-1504.
20. Iwatsubo T. Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease. J.Neurol. 2003, 250(Suppl 3):III11-14.
21. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time courseandmorphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995, 4:257-269.
22. Jiang Q., Yan Z., Feng J. Neurotrophic factors stabilize microtubules and protect against rotenone toxicity on dopaminergic neurons. J.Biol. Chem. 2006, 281:29391-29400.
23. Kopecky B., Decook R., Fritzsch B. Mutational ataxia resulting from abnormal vestibular acquisition and processing is partially compensated for. Behav. Neurosci. 2012, 126:301-313.
24. Kruse S.E., Watt W.C., Marcinek D.J., Kapur R.P., Schenkman K.A., Palmiter R.D. Mice with mitochondrial complex I deficiency develop a fatal encephalomyopathy. Cell Metab. 2008, 7:312-320.
25. Lang A.E., Blair R.D. Parkinson's disease in 1984: an update. Can. Med. Assoc. J. 1984, 131:1031-1037.
26. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
27. Lee F.J., Liu F., Pristupa Z.B., Niznik H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 2001, 15:916-926.
28. Lee Y., Dawson V.L., Dawson T.M. Animal models of Parkinson's disease: vertebrate genetics. Cold Spring Harb. Perspect. Med. 2012, 2.
29. Li X., Patel J.C., Wang J., Avshalumov M.V., Nicholson C., Buxbaum J.D., Elder G.A., Rice M.E., Yue Z. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J.Neurosci. 2010, 30:1788-1797.
30. Lima M.M., Martins E.F., Delattre A.M., Proenca M.B., Mori M.A., Carabelli B., Ferraz A.C. Motor and non-motor features of Parkinson's disease - a review of clinical and experimental studies. CNS Neurol. Disord. Drug Targets 2012, 11:439-449.
31. Liou A.K., Zhou Z., Pei W., Lim T.M., Yin X.M., Chen J. BimEL up-regulation potentiates AIF translocation and cell death in response to MPTP. FASEB J. 2005, 19:1350-1352.
32. Liu W., Acin-Perez R., Geghman K.D., Manfredi G., Lu B., Li C. Pink1 regulates the oxidative phosphorylation machinery via mitochondrial fission. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12920-12924.
33. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T., Kagawa Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 1989, 163:1450-1455.
34. Morais V.A., Haddad D., Craessaerts K., De Bock P.J., Swerts J., Vilain S., Aerts L., Overbergh L., Grunewald A., Seibler P., Klein C., Gevaert K., Verstreken P., De Strooper B. PINK1 loss-of-function mutations affect mitochondrial complex I activity via NdufA10 ubiquinone uncoupling. Science 2014, 344:203-207.
35. Morais V.A., Verstreken P., Roethig A., Smet J., Snellinx A., Vanbrabant M., Haddad D., Frezza C., Mandemakers W., Vogt-Weisenhorn D., Van Coster R., Wurst W., Scorrano L., De Strooper B. Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function. EMBO Mol. Med. 2009, 1:99-111.
36. Palin E.J., Paetau A., Suomalainen A. Mesencephalic complex I deficiency does not correlate with parkinsonism in mitochondrial DNA maintenance disorders. Brain 2013, 136(Pt 8):2379-2392.
37. Pan-Montojo F., Anichtchik O., Dening Y., Knels L., Pursche S., Jung R., Jackson S., Gille G., Spillantini M.G., Reichmann H., Funk R.H. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 2010, 5:e8762.
38. Pan Y.W., Chan G.C.K., Kuo C.T., Storm D.R., Xia Z. Inhibition of adult neurogenesis by inducible and targeted deletion of ERK5 mitogen-activated protein kinase specifically in adult neurogenic regions impairs contextual fear extinction and remote fear memory. J.Neurosci. 2012, 32:6444-6455.
39. Pandya M., Kubu C.S., Giroux M.L. Parkinson disease: not just a movement disorder. Cleve. Clin. J. Med. 2008, 75:856-864.
40. Parker W.D., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 1989, 26:719-723.
41. Petroske E., Meredith G.E., Callen S., Totterdell S., Lau Y.S. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 2001, 106:589-601.
42. Petruzzella V., Papa S. Mutations in human nuclear genes encoding for subunits of mitochondrial respiratory complex I: the NDUFS4 gene. Gene 2002, 286:149-154.
43. Petruzzella V., Vergari R., Puzziferri I., Boffoli D., Lamantea E., Zeviani M., Papa S. Anonsense mutation in the NDUFS4 gene encoding the 18 kDa (AQDQ) subunit of complex I abolishes assembly and activity of the complex in a patient with Leigh-like syndrome. Hum. Mol. Genet. 2001, 10:529-535.
44. Pinna A., Tronci E., Schintu N., Simola N., Volpini R., Pontis S., Cristalli G., Morelli M. Anew ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology 2010, 58:613-623.
45. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V.L., Dawson T.M. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:4565-4571.
46. Quintana A., Kruse S.E., Kapur R.P., Sanz E., Palmiter R.D. Complex I deficiency due to loss of Ndufs4 in the brain results in progressive encephalopathy resembling Leigh syndrome. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10996-11001.
47. Ren Y., Liu W., Jiang H., Jiang Q., Feng J. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J.Biol. Chem. 2005, 280:34105-34112.
48. Rommelfanger K.S., Edwards G.L., Freeman K.G., Liles L.C., Miller G.W., Weinshenker D. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:13804-13809.
49. Scacco S., Petruzzella V., Budde S., Vergari R., Tamborra R., Panelli D., van den Heuvel L.P., Smeitink J.A., Papa S. Pathological mutations of the human NDUFS4 gene of the 18-kDa (AQDQ) subunit of complex I affect the expression of the protein and the assembly and function of the complex. J.Biol. Chem. 2003, 278:44161-44167.
50. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 1:1269.
51. Sherer T.B., Kim J.H., Betarbet R., Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 2003, 179:9-16.
52. Sidhu A., Wersinger C., Vernier P. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. FEBS Lett. 2004, 565:1-5.
53. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 1999, 21:70-71.
54. Sterky F.H., Hoffman A.F., Milenkovic D., Bao B., Paganelli A., Edgar D., Wibom R., Lupica C.R., Olson L., Larsson N.G. Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons. Hum. Mol. Genet. 2012, 21:1078-1089.
55. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci. 2007, 30:244-250.
56. Tanner C.M., Kamel F., Ross G.W., Hoppin J.A., Goldman S.M., Korell M., Marras C., Bhudhikanok G.S., Kasten M., Chade A.R., Comyns K., Richards M.B., Meng C., Priestley B., Fernandez H.H., Cambi F., Umbach D.M., Blair A., Sandler D.P., Langston J.W. Rotenone, paraquat, and Parkinson's disease. Environ. Health Perspect. 2011, 119:866-872.
57. Turiault M., Parnaudeau S., Milet A., Parlato R., Rouzeau J.D., Lazar M., Tronche F. Analysis of dopamine transporter gene expression pattern - generation of DAT-iCre transgenic mice. FEBS J. 2007, 274:3568-3577.
58. van den Heuvel L., Ruitenbeek W., Smeets R., Gelman-Kohan Z., Elpeleg O., Loeffen J., Trijbels F., Mariman E., de Bruijn D., Smeitink J. Demonstration of a new pathogenic mutation in human complex I deficiency: a 5-bp duplication in the nuclear gene encoding the 18-kD (AQDQ) subunit. Am. J. Hum. Genet. 1998, 62:262-268.
59. Vilain S., Esposito G., Haddad D., Schaap O., Dobreva M.P., Vos M., Van Meensel S., Morais V.A., De Strooper B., Verstreken P. The yeast complex I equivalent NADH dehydrogenase rescues pink1 mutants. PLoS Genet. 2012, 8:e1002456.
60. Vogel R.O., van den Brand M.A., Rodenburg R.J., van den Heuvel L.P., Tsuneoka M., Smeitink J.A., Nijtmans L.G. Investigation of the complex I assembly chaperones B17.2L and NDUFAF1 in a cohort of CI deficient patients. Mol. Genet. Metab. 2007, 91:176-182.